Equities analysts expect that Abeona Therapeutics Inc (NASDAQ:ABEO) will report earnings of ($0.29) per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Abeona Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.19). Abeona Therapeutics reported earnings per share of ($0.19) during the same quarter last year, which would indicate a negative year-over-year growth rate of 52.6%. The company is expected to announce its next earnings report on Friday, March 15th.
On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($1.16) to ($0.74). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.66) to ($0.82). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Monday, November 12th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.11). The firm had revenue of $1.71 million during the quarter, compared to analyst estimates of $1.02 million. Abeona Therapeutics had a negative net margin of 843.14% and a negative return on equity of 27.69%.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its holdings in Abeona Therapeutics by 1.4% in the third quarter. FMR LLC now owns 7,191,492 shares of the biopharmaceutical company’s stock valued at $92,051,000 after buying an additional 97,185 shares during the period. BlackRock Inc. lifted its holdings in Abeona Therapeutics by 1.6% in the third quarter. BlackRock Inc. now owns 2,220,116 shares of the biopharmaceutical company’s stock valued at $28,418,000 after buying an additional 35,610 shares during the period. Vanguard Group Inc. lifted its holdings in Abeona Therapeutics by 7.6% in the third quarter. Vanguard Group Inc. now owns 1,539,008 shares of the biopharmaceutical company’s stock valued at $19,699,000 after buying an additional 108,333 shares during the period. Millennium Management LLC lifted its holdings in Abeona Therapeutics by 5.3% in the second quarter. Millennium Management LLC now owns 964,839 shares of the biopharmaceutical company’s stock valued at $15,437,000 after buying an additional 48,583 shares during the period. Finally, Nexthera Capital LP lifted its holdings in Abeona Therapeutics by 35.6% in the third quarter. Nexthera Capital LP now owns 849,979 shares of the biopharmaceutical company’s stock valued at $10,880,000 after buying an additional 223,175 shares during the period. Institutional investors and hedge funds own 75.11% of the company’s stock.
NASDAQ:ABEO traded up $0.39 on Friday, reaching $8.20. The stock had a trading volume of 649,696 shares, compared to its average volume of 613,350. The firm has a market cap of $374.45 million, a PE ratio of -12.42 and a beta of 1.77. Abeona Therapeutics has a 1-year low of $6.94 and a 1-year high of $22.00.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Recommended Story: How is inflation measured?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.